Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stem Cell Therapeutics has received two new Prolactin corresponding patents that strengthen its intellectual property landscape through US and Australia.
Subscribe to our email newsletter
According to the company, the patents cover the use of prolactin alone, as well as in combination with other therapeutics that augment recovery and therefore provide a broad base of protection. These are the first patents to issue in Prolactin patent family.
This intellectual property supports programs currently under development using prolactin alone or with anti-inflammatories to treat multiple sclerosis and using a combination of prolactin and EPO to treat other neurodegenerative diseases.
Alan Moore, President and CEO of Stem Cell, said: “We have the exclusive right to the use of prolactin for treating neurodegenerative diseases and therefore have a strong foundation to develop many possible products using prolactin, either as a single therapeutic or in combination with other neurogenic agents.”